The article provides an overview of analyst ratings for Ionis Pharmaceuticals, with a mix of bullish, somewhat bullish, indifferent, and somewhat bearish opinions. The average 12-month price target has increased by 6.34% from the previous average, indicating a potential upside. However, the mixed ratings suggest that the short-term impact on the stock price is uncertain, leading to a neutral score.